CONSULTING AGREEMENT [May Orfali, MD, MBA]Consulting Agreement • March 14th, 2022 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), is made as of October 13, 2021 (the “Effective Date”) by and between Sigilon Therapeutics, Inc. (the “Company”), with offices at 100 Binney Street, Suite 600, Cambridge, MA 02142, and Rare Disease and Oncology Consulting, LLC, (the “Consultant”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.Sixth Amendment • March 14th, 2022 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This Sixth Amendment (“Sixth Amendment”), effective as of February 1, 2022 (the “Sixth Amendment Effective Date”), is made by and between the Massachusetts Institute of Technology, a nonprofit research institution having a principal address at 77 Massachusetts Avenue, Cambridge, MA 02139 (“MIT”) and Sigilon Therapeutics, Inc. (fka Sigilon, Inc.) a Delaware corporation, having a principal address at 100 Binney Street, Cambridge, MA 02142 (“Company”) (each individually a “Party” and collectively the “Parties”), and amends that certain Exclusive Patent License Agreement between the Parties dated as of February 8, 2016, as amended (collectively, the “License Agreement”). Capitalized terms used herein without definition shall have the meaning given such terms in the License Agreement.
August 4, 2021 BY HAND & ELECTRONIC DELIVERY Deya Corzo, M.D.Letter Agreement • March 14th, 2022 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
The purpose of this letter agreement (this “Agreement”) is to confirm the terms of the remainder of your employment with Sigilon Therapeutics, Inc. (the “Company”) and your resignation from your employment with the Company, as follows:
